eprintid: 20746
rev_number: 14
eprint_status: archive
userid: 1589
dir: disk0/00/02/07/46
datestamp: 2016-05-25 13:33:28
lastmod: 2024-03-30 13:20:30
status_changed: 2016-05-25 13:33:28
type: article
metadata_visibility: show
creators_name: Pfeil, Johannes
creators_name: Listl, Stefan
creators_name: Hoffmann, Georg F.
creators_name: Kölker, Stefan
creators_name: Lindner, Martin
creators_name: Burgard, Peter
title: Newborn screening by tandem mass spectrometry for glutaric aciduria type 1: a cost-effectiveness analysis
subjects: ddc-610
divisions: i-910500
divisions: i-910800
abstract: Background: Glutaric aciduria type I (GA-I) is a rare metabolic disorder caused by inherited deficiency of glutaryl-CoA dehydrogenase. Despite high prognostic relevance of early diagnosis and start of metabolic treatment as well as an additional cost saving potential later in life, only a limited number of countries recommend newborn screening for GA-I. So far only limited data is available enabling health care decision makers to evaluate whether investing into GA-I screening represents value for money. The aim of our study was therefore to assess the cost-effectiveness of newborn screening for GA-I by tandem mass spectrometry (MS/MS) compared to a scenario where GA-I is not included in the MS/MS screening panel.   Methods: We assessed the cost-effectiveness of newborn screening for GA-I against the alternative of not including GA-I in MS/MS screening. A Markov model was developed simulating the clinical course of screened and unscreened newborns within different time horizons of 20 and 70 years. Monte Carlo simulation based probabilistic sensitivity analysis was used to determine the probability of GA-I screening representing a cost-effective therapeutic strategy.   Results: Within a 20 year time horizon, GA-I screening averts approximately 3.7 DALYs (95% CI 2.9 – 4.5) and about one life year is gained (95% CI 0.7 – 1.4) per 100,000 neonates screened initially . Moreover, the screening programme saves a total of around 30,682 Euro (95% CI 14,343 to 49,176 Euro) per 100,000 screened neonates over a 20 year time horizon.   Conclusion: Within the limitations of the present study, extending pre-existing MS/MS newborn screening programmes by GA-I represents a highly cost-effective diagnostic strategy when assessed under conditions comparable to the German health care system.
date: 2013
publisher: BioMed Central
id_scheme: DOI
ppn_swb: 1656791854
own_urn: urn:nbn:de:bsz:16-heidok-207469
language: eng
bibsort: PFEILJOHANNEWBORNSCR2013
full_text_status: public
publication: Orphanet Journal of Rare Diseases
volume: 8
number: 167
place_of_pub: London
pagerange: 1-11
issn: 1750-1172
citation:   Pfeil, Johannes ; Listl, Stefan ; Hoffmann, Georg F. ; Kölker, Stefan ; Lindner, Martin ; Burgard, Peter  (2013) Newborn screening by tandem mass spectrometry for glutaric aciduria type 1: a cost-effectiveness analysis.  Orphanet Journal of Rare Diseases, 8 (167).  pp. 1-11.  ISSN 1750-1172     
document_url: https://archiv.ub.uni-heidelberg.de/volltextserver/20746/1/13023_2013_Article_803.pdf